EU weight-management indication
According to the EMA, Mounjaro is indicated alongside a reduced-calorie diet and increased physical activity for adults with a BMI of at least 30 kg/m², or 27 to under 30 kg/m² when at least one weight-related comorbidity is present.
How it differs from Wegovy
Wegovy contains semaglutide and acts on the GLP-1 receptor. Mounjaro contains tirzepatide and acts on GIP and GLP-1 receptors. Choice should not be based only on expected weight loss. Safety, tolerance, medical history and availability also matter.
Adverse effects and contraindications
Specific risks and contraindications should be checked in the current product information. New or severe symptoms require clinical advice.
Price and availability
Price varies by country, strength, pack, pharmacy and reimbursement status. There is no single meaningful “EU price”.
Sources and review
Information is based on European regulatory sources. Availability, reimbursement and prescribing rules vary between EU countries.
Sources last checked: 1 September 2026.